Back to today’s briefing

Story perspectives

Eli Lilly’s Drug Cuts Heart Disease Risk by 95%

3/30/2025

29 2

Summary

Story summary

Eli Lilly's groundbreaking drug, lepodisiran, has shown remarkable potential in a midstage trial, slashing lipoprotein(a) levels by an astonishing 95%. This could be a game-changer for the 64 million Americans at risk of heart disease. With no serious side effects noted, the next step is larger trials to validate its effects on heart attacks and strokes.

1 of 1

Story summary

Eli Lilly's groundbreaking drug, lepodisiran, has shown remarkable potential in a midstage trial, slashing lipoprotein(a) levels by an astonishing 95%. This could be a game-changer for the 64 million Americans at risk of heart disease. With no serious side effects noted, the next step is larger trials to validate its effects on heart attacks and strokes.